The biological target is a self-reinforcing cycle between oxidation and inflammation. Reactive oxygen species produced by mitochondria and NADPH oxidases include superoxide, hydrogen peroxide and the hydroxyl radical, which differ in reactivity, diffusion range and biological effects. Some act as signals at physiological concentrations, but excess production can overwhelm superoxide dismutase, catalase and glutathione peroxidase. Lipid peroxidation then damages membranes and proteins, while iron-dependent, lipid-peroxidation-mediated ferroptosis can contribute to organ injury. Ischemia followed by reoxygenation can produce a sudden oxidant surge, glutathione depletion and widespread cellular damage in the heart, liver and kidney. A material therefore cannot treat all reactive species as one interchangeable target: its activity must match the species, concentration, location and timing characteristic of a particular injury.

Oxidized lipids, mitochondrial DNA, HMGB1 protein and other damage-associated molecular patterns activate innate immune sensors and NF-κB signaling, increasing expression of cytokines such as TNF-α, IL-1β and IL-6. Neutrophils and macrophages recruited to the injury then generate additional reactive species through respiratory and NADPH oxidase activity. Reactive oxygen species can also activate the NLRP3 inflammasome, mature IL-1β and favor pro-inflammatory, M1-like macrophages over the M2-like state associated with debris clearance and repair. The Nrf2/Keap1 pathway provides a counter-regulatory mechanism: under oxidative stress, Nrf2 separates from Keap1, enters the nucleus and activates protective genes including HO-1 and NQO1, while also suppressing some macrophage cytokine responses. The review uses the ROS–NF-κB–Nrf2 axis as a design framework, while stressing that these pathways are not a simple linear circuit and can vary by cell type, tissue and repair stage.

Under these conditions, conventional scaffolds can inadvertently amplify injury. Their mechanics, porosity and degradation rate may be appropriate for tissue formation, but passive architecture does not manage local redox or immune state. Oxidants can deactivate growth factors, cells and vesicles, while implant surfaces may provoke a foreign-body response in which macrophages fuse into giant cells and surround the material with an avascular fibrous capsule. Biodegradation can add further stress: acidic products released by common aliphatic polyesters such as PLGA can burden tissue already struggling with oxidative stress. The review consequently treats scaffolds as active participants in implantation outcomes. An effective construct should scavenge excessive reactive species without eliminating the lower concentrations needed for normal signaling, while helping immune cells progress from destructive inflammation toward reparative activity.

The available bioactive agents make different trade-offs. Endogenous enzymes such as superoxide dismutase and catalase are specific and biocompatible, but they are fragile outside a protective matrix. They also function as a cascade: superoxide dismutase converts superoxide to hydrogen peroxide, which catalase or glutathione peroxidase must subsequently remove, so delivering one enzyme without an appropriate partner can leave peroxide accumulating. Plant polyphenols including curcumin, tannic acid, resveratrol and quercetin can directly trap radicals and influence Nrf2 and NF-κB signaling, but they are consumed stoichiometrically and have a finite protective window. Curcumin also presents poor bioavailability and hydrophobicity. Extracellular vesicles provide broader, cargo-driven immunomodulation without the uncontrolled engraftment risks of whole cells, yet their heterogeneous composition, rapid clearance and difficult standardization are major liabilities. Catalytic nanomaterials offer another profile: ceria, manganese-based nanozymes and Prussian blue can cycle between chemical states and continue scavenging after small-molecule antioxidants are depleted, although toxicity, intracellular accumulation and clearance remain unresolved concerns.

The surrounding matrix determines whether an agent retains enough activity to affect the injury. Collagen, gelatin and decellularized extracellular matrix offer native adhesion and remodeling cues, but can require crosslinking and may vary between batches; donor availability, cost and immunogenicity complicate scale-up. Synthetic polymers permit reproducible tuning of mechanics and degradation, yet may be biologically inert or generate inflammatory byproducts. Gelatin methacryloyl retains collagen-derived binding sites while allowing photocrosslinking and mechanical adjustment. Injectable hydrogels can conform to irregular defects and form through temperature, ion or enzymatic triggers, making them attractive for cardiac, hepatic and renal sites, but their limited load-bearing capacity confines them largely to soft tissues. Crosslinking conditions must also remain gentle enough to preserve cells and vesicles. Intrinsically antioxidant polymers containing polyphenolic or polydopamine groups distribute scavenging capacity through the structure and avoid some release-related uncertainties, although structural damage then reduces therapeutic function and their finite scavenging capacity may still require supplementation with regenerable nanozymes.

Payload protection and timely release can work against each other. A dense network may preserve enzymes or extracellular vesicles while restricting substrate access, cell interaction or timely cargo release. Hydrogel mesh size, fibrous scaffolds, physical binding and covalent conjugation therefore generate different retention–bioactivity balances. Loading bioactive agents after scaffold fabrication can separate delicate cargo from electrospinning solvents, printing shear and crosslinking chemistry. Release can also be tied to the injury itself. Boronic esters, thioketals, diselenides and disulfides can be cleaved by hydrogen peroxide or related oxidants, triggering payload release in proportion to local oxidative stress. Their cleavage may consume reactive species while releasing cargo, and some designs couple cargo release to degradation of the network itself. Systems may also respond to acidic pH or elevated enzyme activity. Multi-compartment structures, core–shell fibers and layered hydrogels can stage an early antioxidant response before slower immunomodulatory or regenerative signals appear, although the review cautions that most current “responsive” systems approximate biological timing through preprogrammed kinetics rather than true closed-loop feedback.

Organ-specific requirements further narrow the appropriate design. In the heart, the acute reactive-oxygen-species surge during reperfusion and the organ’s continuous mechanical activity favor injectable, in situ-forming systems with release timed to the oxidative burst. In preclinical studies, reactive-scavenging, extracellular-matrix-mimetic hydrogels that supported pro-resolving macrophage polarization reduced infarct size and improved contractile function, while metabolism-supporting hydrogels reduced adverse ventricular remodeling. The liver and kidney provide a defined intervention window during transplantation, when cold ischemia and controlled reperfusion create predictable injury. Machine perfusion may allow enzyme-mimetic materials to act before reperfusion, although rapid flow may limit their residence time. Neural repair adds the physical obstruction of the glial scar, requiring oxidative stress to be contained before a mechanically matched substrate can support axonal ingrowth. Chronic skin wounds have a persistent, low-grade inflammatory profile that may be better suited to durable ceria-embedded collagen systems than to rapidly depleted antioxidants.

The preclinical evidence remains uneven and does not establish clinical benefit. Cell models based on hydrogen-peroxide exposure or oxygen–glucose deprivation followed by reoxygenation provide controlled screening, but they cannot reproduce perfusion, mechanical loading, immune-cell trafficking or the spatially structured reactive-oxygen-species profile of an intact organ. Animal models include circulation, immune competence and realistic timing, yet young, healthy rodents differ from the older, diabetic or otherwise comorbid patients most likely to require such implants. Organ-on-chip systems can incorporate human cells, immune interactions and controlled ischemia–reperfusion cycles, but they remain partial models rather than substitutes for animal studies or clinical trials. Cardiac and cutaneous applications are more mature in the reviewed literature, whereas hepatic, renal and neural applications are earlier and more dependent on mechanistic inference. Head-to-head studies are also largely missing, so the evidence does not yet show that every dual-function construct outperforms a well-optimized single-function treatment.

Translation is constrained less by an absence of plausible mechanisms than by the difficulty of producing standardized, defensible products. Extracellular-vesicle cargo is vulnerable to oxidation, and curcumin can become inactive through the same oxidation it is intended to counter. Implantable constructs must also withstand sterilization, yet heat, irradiation and ethylene oxide can damage sensitive biological or polyphenolic payloads. Combination products that unite a device matrix and drug-like cargo face complex regulatory pathways and require reproducible, quantitative potency assays. A construct acting through a measurable node, such as Nrf2 activation, may be easier to characterize than one producing distributed antioxidant, immune and tissue-remodeling effects. The authors conclude that progress depends less on discovering additional agents than on standardizing potency, manufacturing, storage and validation, while testing constructs in aged, comorbid models and human-relevant microphysiological systems. The central proposal is that future regenerative matrices for pathologically stressed organs should sense and modify their surroundings rather than simply endure them.

Subject of Research: Biohybrid biomaterials that regulate oxidative stress and inflammation during organ repair

Article Title: Engineering antioxidant and anti-inflammatory biohybrid matrices for organ repair: from redox-immune design principles to clinical translation

Article References: Singaravelu, S., Jayaprakash, J., Balu, R., & Paramanathan, B. (2026). Engineering antioxidant and anti-inflammatory biohybrid matrices for organ repair: from redox-immune design principles to clinical translation. Frontiers in Biomaterials Science, 5, Article 1953249. https://doi.org/10.3389/fbiom.2026.1953249

Image Credits: AI Generated

DOI: 10.3389/fbiom.2026.1953249

Keywords: regenerative biomaterials, biohybrid matrices, oxidative stress, inflammation, extracellular vesicles, nanozymes, plant polyphenols, Nrf2 signaling, organ repair, clinical translation, Engineering, antioxidant

The study, led by Greice Itamaro Heiden and colleagues at the Federal University of Santa Catarina in Brazil, set out to answer a question that has lingered over years of laboratory work: does gallic acid’s well-documented anticancer activity in cell cultures actually translate into a living organism, where tumors interact with blood vessels, immune cells, and a host of systemic factors that a petri dish cannot replicate? Most previous evidence came from in vitro experiments on epithelial and blood-derived cancer cell lines, including small-cell lung carcinoma, gastric adenocarcinoma, breast adenocarcinoma, promyelocytic leukemia, and glioma cells. Those studies showed that gallic acid can trigger cell death, halt the cell cycle, and interfere with signaling pathways that drive metastasis and angiogenesis. But the compound’s effects on mesenchymal solid tumors in a whole animal, and its safety profile compared head-to-head with a frontline chemotherapy drug, had never been systematically mapped.

To fill that gap, the team turned to the Sarcoma 180 model, a transplantable mouse tumor that grows rapidly and is widely used for initial screening of potential anticancer agents. Fifty adult male Swiss mice received subcutaneous injections of S-180 ascitic cells, prepared at a standardized concentration of two million viable cells per animal after careful counting with Trypan Blue staining and a Neubauer chamber. Twenty-four hours later, the animals were randomly divided into five groups of ten. Three groups received purified gallic acid, at least 97.5 percent pure, by oral gavage once daily for seven consecutive days at doses of 10, 25, or 50 milligrams per kilogram of body weight. A fourth group received the chemotherapy drug 5-fluorouracil at 25 milligrams per kilogram intraperitoneally, while a control group received only the vehicle solution.

When the animals were euthanized on the eighth day and their tumors weighed, the results showed a clear dose-dependent effect. Mice treated with 25 milligrams per kilogram of gallic acid carried tumors weighing 9.38 grams per 100 grams of body weight, compared with 11.49 grams in the untreated control group, translating to a tumor growth inhibition of roughly 17.6 percent. At the highest dose of 50 milligrams per kilogram, tumor weight fell to 7.21 grams per 100 grams of body weight, an inhibition of 33.7 percent that reached high statistical significance. The lowest dose, 10 milligrams per kilogram, produced no significant effect. As expected, 5-fluorouracil remained the more powerful tumor killer, shrinking tumors by nearly 63 percent, but that potency came at a price the natural compound did not pay.

To understand how gallic acid was attacking the tumors, the researchers performed detailed histopathological and immunohistochemical analyses on the excised tissue. Under the microscope, the S-180 tumors displayed the aggressive features typical of this model: solid sheets of neoplastic cells infiltrating skeletal muscle and fat, perineural invasion, extensive coagulative necrosis, and high mitotic activity exceeding four mitoses per ten high-power fields. The tumor cells showed striking heterogeneity, with rhabdoid, epithelioid, spindle-shaped, and even unusual plant-like forms. Necrotic areas were visibly smaller in both the gallic acid and 5-fluorouracil groups, an early hint that both treatments were pushing tumor cells toward death.

The molecular story that emerged from the immunohistochemistry was remarkably coherent. Gallic acid at 50 milligrams per kilogram cut the expression of Ki-67, a nuclear protein that serves as a standard gauge of cell proliferation, from 14.2 percent of positive nuclei in controls to 9.5 percent. At the same time, it dramatically shifted the balance of the Bcl-2 protein family, which acts as the gatekeeper of mitochondrial suicide: the pro-apoptotic protein Bax rose sharply while the anti-apoptotic Bcl-2 fell, and levels of cleaved caspase-3, the executioner enzyme that dismantles the cell from within, increased significantly. Crucially, cleaved caspase-8, the initiator of the so-called extrinsic death receptor pathway, remained unchanged. Together, this pattern points to preferential activation of the intrinsic, or mitochondrial, apoptotic pathway, in which permeabilization of the mitochondrial membrane releases factors that trigger the caspase cascade and condemn the cell to programmed death.

The study also revealed a third strand in gallic acid’s mechanism: suppression of nuclear factor kappa B, or NF-κB, a transcription factor that functions as a master regulator of tumor cell survival, inflammation, and proliferation. In control animals, 38.4 percent of tumor cell nuclei stained positive for NF-κB; after gallic acid treatment, that figure dropped to 14.4 percent. Because NF-κB drives the production of anti-apoptotic proteins and promotes cell-cycle progression, its inhibition dovetails neatly with the observed increase in apoptosis and the decline in proliferation. The finding is consistent with earlier reports that gallic acid interferes with the MAPK/NF-κB pathway, possibly by reducing phosphorylation and acetylation of the p65 subunit, thereby dampening the factor’s transcriptional output. In effect, the compound appears to attack the tumor from multiple directions at once, strangling growth signals while simultaneously opening the doors to mitochondrial self-destruction.

The safety comparison with 5-fluorouracil may prove to be the study’s most consequential contribution. While the chemotherapy drug achieved greater tumor shrinkage, it devastated the animals’ white blood cell counts, dropping total leukocytes to 2.07 thousand per cubic millimeter, a hallmark of myelosuppression, and caused visible atrophy of the spleen’s white pulp, with shrunken follicles and disrupted lymphoid architecture. Gallic acid, by contrast, preserved leukocyte counts entirely. Liver and kidney weights were unchanged across all groups, serum levels of the liver enzymes AST and ALT stayed within normal ranges, and markers of renal function, urea and creatinine, showed no abnormalities. Histological examination confirmed normal liver and kidney architecture in the gallic acid group. The only notable biochemical shift, a lower AST level in the treated animals, likely reflects reduced tumor burden and less associated muscle damage rather than organ toxicity.

The authors are careful to frame these results as preclinical evidence rather than a promise of a new drug. The S-180 model, though fast and convenient, does not capture the full complexity of human malignancies, and the seven-day treatment window represents only an early snapshot of therapeutic potential. The antitumor efficacy of gallic acid, at roughly half that of 5-fluorouracil, would need substantial improvement, perhaps through combination regimens, novel formulations, or optimized dosing, before human trials could be contemplated. Nevertheless, the mechanistic clarity of the findings is striking: a single dietary polyphenol, taken orally, simultaneously suppressed proliferation, silenced a pro-survival transcription factor, and preferentially ignited the mitochondrial apoptotic pathway, all without measurable harm to blood, liver, or kidney. That combination of efficacy and safety is precisely what makes adjuvant candidates attractive, since the ideal partner to conventional chemotherapy would be one that adds tumor-killing power while shielding patients from the immunosuppression that limits standard treatment. As research into plant-derived anticancer compounds accelerates worldwide, gallic acid has now moved from the cell culture dish into the ranks of molecules with credible, mechanism-backed in vivo evidence, and the next chapter of its story will depend on whether that mitochondrial trigger can be pulled hard enough, and safely enough, in the clinic.

Subject of Research: Antitumor activity and safety of orally administered gallic acid in the murine Sarcoma 180 cancer model

Article Title: Antitumor efficacy and safety profile of gallic acid in the murine sarcoma 180 model

Article References: Heiden, G. I., Costa, M. A. D. S., Alfaia Silva, C., Carvalho, F. M. D. A. D., Amaral, R. G., Rivero, E. R. C., Modolo, F., Gondak, R., & de Albuquerque-Júnior, R. L. C. (2026). Antitumor efficacy and safety profile of gallic acid in the murine sarcoma 180 model. Medical Oncology, 43(11), Article 331. https://doi.org/10.1007/s12032-026-03455-8

Image Credits: AI Generated

DOI: 10.1007/s12032-026-03455-8

Keywords: gallic acid, Sarcoma 180, apoptosis, NF-κB, Ki-67, 5-fluorouracil, polyphenols, preclinical study, mitochondrial pathway, myelosuppression, cancer therapy, natural compounds

Reactive oxygen species, or ROS, include free radicals such as superoxide and hydroxyl radicals as well as non-radical species like hydrogen peroxide and singlet oxygen. They arise from endogenous sources, chiefly mitochondrial metabolism, and from exogenous exposures including ultraviolet radiation, pollutants and drugs. In healthy cells, ROS act as essential signaling molecules, but when their production outpaces the cell’s antioxidant defenses, oxidative stress ensues. The review emphasizes that this imbalance is a hallmark of cancer cells, which typically generate more localized ROS than their normal counterparts due to elevated metabolic activity, mitochondrial dysfunction, oncogene activation and increased activity of oxidases, cyclooxygenases and lipoxygenases.

The consequences of excess ROS reach far beyond simple DNA breakage. Hydroxyl radicals can attack purines and pyrimidines, producing base modifications such as 8-oxo-7,8-dihydroguanine, one of the most reliable biomarkers of oxidative DNA damage. In normal human cells, 8-oxoGua adducts form at a rate of roughly one per 100,000 guanine residues, but in smokers this rate rises by more than 30 percent, and patients with lung, breast or prostate cancer show levels approximately 50 percent higher than healthy individuals. When repair mechanisms such as 8-oxoguanine glycosylase fail under persistent oxidative stress, mutations accumulate in critical genes including the RAS oncogene and the TP53 tumor suppressor, fueling genomic instability and malignant transformation.

Perhaps the most compelling section of the review concerns the epigenetic consequences of oxidative stress. ROS can drive both global DNA hypomethylation and site-specific hypermethylation of tumor suppressor gene promoters, a pattern reversal that is characteristic of cancer cells. The mechanistic links are intricate: oxidative stress alters the activity of DNA methyltransferases and histone modifiers, while depletion of glutathione reduces levels of S-adenosylmethionine, the universal methyl group donor required by DNA methyltransferases and histone methyltransferases. The oxidized base lesion 8-hydroxydeoxyguanosine interferes with methyltransferase binding to nearby cytosines, and hydroxylation of 5-methylcytosine to 5-hydroxymethylcytosine can reduce cytosine methylation by as much as 90 percent, according to work by Valinluck and Sowers cited in the review.

The authors also describe how hydrogen peroxide exposure recruits DNMT1 to damaged chromatin, where it joins complexes containing DNMT3B, sirtuins and members of the polycomb repressive complex 4, leading to silencing marks such as H3K27me3 and loss of active marks like H3K4me3 and H4K16ac. In kidney epithelial cells, chronic oxidative stress converted normal cells into cancerous ones, altering the expression of DNMT1, DNMT3a, MBD4, HDAC1, HMT1 and HAT1, and this malignant phenotype was partially reversed by treatment with the demethylating agent 5-aza-2′-deoxycytidine, underscoring the reversibility of the epigenetic machinery. Similar ROS-driven methylation changes have been documented for tumor suppressor genes such as RUNX3 in colorectal cancer and p16 in the progression from Barrett’s esophagus to esophageal adenocarcinoma.

ROS also orchestrate inflammation and immune evasion, two processes intimately entwined with epigenetics. Elevated ROS activates signaling cascades including NF-kB, MAPK, STAT3 and PI3K/AKT, promoting uncontrolled proliferation, angiogenesis and epithelial-mesenchymal transition, the program by which cancer cells acquire migratory and invasive properties. At the same time, ROS suppresses T cells and natural killer cells and skews macrophages toward an M2 phenotype that supports tumor vascularization. The Nrf2-KEAP1 pathway emerges as a double-edged sword: in normal cells, Nrf2 activation induces phase II detoxification and antioxidant enzymes, but in established cancers, sustained Nrf2 activation confers drug resistance and cellular immortality.

This duality is precisely where polyphenols display their therapeutic versatility. Compounds such as sulforaphane from cruciferous vegetables, curcumin from turmeric, epigallocatechin-3-gallate from green tea, genistein from soy, quercetin from onions and apples, and resveratrol from grapes and berries can each act as either antioxidant or pro-oxidant depending on context and concentration. As antioxidants, they activate Nrf2, promote its nuclear localization and stimulate the synthesis of glutathione S-transferase, heme oxygenase 1, NADPH quinone oxidoreductase, catalase and superoxide dismutase, thereby neutralizing ROS before they can damage the epigenome. As pro-oxidants, they raise ROS levels in drug-resistant cancer cells, inhibit Nrf2 and trigger apoptosis, sensitizing tumors to chemotherapy.

The epigenetic footprints of individual polyphenols are strikingly specific. Sulforaphane inhibited DNMT1 and DNMT3a in breast cancer cells, downregulated the telomerase reverse transcriptase hTERT, and remodeled chromatin at the hTERT promoter with increased H3K9 acetylation and decreased H3K9 and H3K27 trimethylation. Curcumin reversed hypermethylation of the glutathione S-transferase pi 1 promoter in MCF-7 breast cancer cells, re-expressed the hypermethylated BRCA1 gene through TET1-mediated demethylation, upregulated miR-15a and miR-16 to suppress the anti-apoptotic protein Bcl-2, and even reversed multidrug resistance in colorectal cancer cells by increasing ROS and diminishing Nrf2 expression. Genistein demethylated and reactivated p16INK4a and BTG3, while EGCG reactivated the silenced tumor suppressors p16INK4a, p21CIP/WAF1 and Wnt inhibitory factor 1 through promoter demethylation and histone acetylation changes.

The review is candid about the obstacles standing between laboratory promise and clinical practice. Most of the evidence comes from in vitro models, and animal studies must precede any prescription in clinical settings. Polyphenols suffer from poor water solubility and low oral bioavailability, although bio-based nanocarriers, including polymeric nanoparticles, nanocrystals, cyclodextrins, nano-caseins and electrospun nanofibers, are being developed to overcome these limitations. Dosing also demands caution: low concentrations of quercetin reduced ROS and antagonized the pro-oxidant mechanism of cisplatin in ovarian cancer cells, potentially undermining treatment, while high doses of green tea catechins have been associated with hepatotoxicity and worsened colon carcinogenesis in experimental animals. A study by Salvador and colleagues further showed that ROS-generating therapeutic agents can be more toxic to normal cells than to p53-negative tumors, highlighting the need to select agents and doses that spare healthy tissue.

Even with these caveats, the synthesis offered by Raina and colleagues is a compelling case that the epigenetic damage wrought by oxidative stress is not a one-way street. Because epigenetic modifications are inherently reversible, and because polyphenols can simultaneously scavenge ROS, modulate Nrf2, dampen NF-kB-driven inflammation and recalibrate DNA methyltransferases, histone acetyltransferases and histone deacetylases, these dietary compounds occupy a uniquely favorable position in the search for chemopreventive and chemosensitizing agents. The authors call for further research into the biological processes underlying ROS-induced epigenetic alterations, the interaction between polyphenols and the gut microbiome, and the precise concentrations required for anti-cancer effects. If those questions can be answered, the humble molecules found in broccoli, turmeric, green tea and grapes may yet earn a place alongside conventional therapies in the oncologist’s arsenal.

Subject of Research: ROS-induced epigenetic alterations in carcinogenesis and their reversal by dietary polyphenols

Article Title: Polyphenols reverse ROS induced epigenetic alterations in the process of carcinogenesis

Article References: Raina, R., Bhatt, R., Hussain, A., Afroze, N., & Hussain, A. (2025). Polyphenols reverse ROS induced epigenetic alterations in the process of carcinogenesis. Epigenetics Communications, 5(1), Article 5. https://doi.org/10.1186/s43682-025-00034-2

Image Credits: AI Generated

DOI: 10.1186/s43682-025-00034-2

Keywords: reactive oxygen species, polyphenols, epigenetics, carcinogenesis, Nrf2 pathway, DNA methylation, histone modification, sulforaphane, curcumin, EGCG, chemoprevention, oxidative stress

The research team, led by Shuning Liu and Chang Liu of Beijing Sport University together with collaborators from Lanzhou University, Wuhan Sports University and other institutions, set out to determine whether syringaresinol could activate a well-known signaling circuit that connects muscle and fat tissue. This circuit runs through SIRT1, a NAD-dependent deacetylase enzyme long associated with calorie restriction and mitochondrial health, which in turn activates PGC-1α, the master regulator of mitochondrial biogenesis. PGC-1α then promotes expression of FNDC5, the membrane protein whose cleaved extracellular fragment is the hormone irisin. Irisin released into the bloodstream acts on adipose tissue, encouraging white fat cells to adopt brown-fat-like characteristics—producing heat, burning calories, and reshaping systemic energy balance.

In the laboratory phase of the study, the team used differentiated C2C12 myotubes, the standard cell model for mature skeletal muscle, and treated them with syringaresinol alongside two chemical reference compounds: SRT1720, a potent SIRT1 activator, and EX-527, a selective SIRT1 inhibitor. The results were striking. Myotubes exposed to syringaresinol showed increased irisin-related readouts, elevated ATP content, and higher citrate synthase activity, a classic indicator of enhanced mitochondrial oxidative capacity. At the molecular level, the compound produced transcriptional changes consistent with SIRT1/PGC-1α/FNDC5 activation and increased the abundance of both SIRT1 and PGC-1α proteins, placing syringaresinol squarely in the same mechanistic territory as established metabolic interventions.

The critical question was whether these effects genuinely depended on SIRT1. The inhibitor experiments provided the answer: when EX-527 blocked SIRT1 activity, the syringaresinol-driven responses in the myotubes were substantially attenuated. This pharmacological loss-of-function evidence supports the conclusion that SIRT1 signaling sits upstream of the observed changes and is required for syringaresinol to exert its influence on irisin production and mitochondrial markers in muscle cells. It is a level of mechanistic rigor that many plant-compound studies lack, and it gives the findings considerably more weight than simple correlation would allow.

But cell culture only goes so far, and the team therefore moved to a living system. Mice fed a high-fat diet—the standard model of diet-induced obesity—received syringaresinol by oral gavage at either a low or a high dose for 18 weeks, a substantial intervention period that allowed metabolic adaptations to fully develop. Over those weeks, the treated animals gained significantly less body weight than their untreated high-fat-diet counterparts. Crucially, food intake did not differ significantly between groups, which means the anti-obesity effect could not be explained by reduced appetite or caloric restriction. Something else was happening to the animals’ energy economy.

That something else appears to be a combination of circulating irisin and fat-tissue remodeling. Plasma measurements revealed that syringaresinol-treated mice had elevated levels of circulating irisin, consistent with the muscle-cell findings. The compound also improved lipid profiles, lowering the LDL-C/HDL-C ratio—a marker of cardiometabolic risk. In inguinal white adipose tissue, the subcutaneous fat depot most amenable to browning, expression of PGC-1α, uncoupling protein 1 (Ucp1), and Pparγ all increased. Ucp1 is the molecular signature of thermogenically active brown and beige fat: it short-circuits the mitochondrial proton gradient to generate heat instead of ATP, effectively burning calories as warmth. Its upregulation in white fat depots is the hallmark of the browning process that irisin was originally discovered to induce.

The original discovery of irisin in 2012 by Bruce Spiegelman’s group demonstrated that a PGC-1α-dependent myokine released from exercising muscle could drive brown-fat-like development in white fat and stimulate thermogenesis, and the field has since been searching for safe, practical ways to amplify this axis in people who cannot simply exercise their way out of metabolic disease. Recombinant irisin has been shown to induce weight loss in obese mice by increasing energy consumption and thermogenesis, and irisin has been linked to improved fatty acid oxidation and glucose utilization through AMPK signaling. Syringaresinol now emerges as a candidate nutritional tool for tapping into that same axis, working through the upstream SIRT1 node that is also targeted by compounds such as resveratrol and, more recently, by other dietary polyphenols like sesamol.

Syringaresinol itself is no newcomer to scientific attention. Prior studies have reported that it modulates gut microbiota and delays immunosenescence in middle-aged mice, protects against type 1 diabetic cardiomyopathy by reducing inflammation and oxidative stress, attenuates osteoarthritis through the NF-κB pathway, and even shows promise in models of cognitive decline and Alzheimer’s-related pathology. Toxicological testing of syringaresinol and its enterolignan metabolites has been carried out, and a comprehensive 2025 review has catalogued its plant sources, pharmacological activities, and pharmacokinetic characteristics. The new study adds weight management and the muscle–adipose endocrine axis to this expanding portfolio, positioning the compound as a multi-target nutritional agent rather than a single-action drug.

The researchers are appropriately careful about the limits of their evidence. In the published paper, they note that while the findings support syringaresinol as a candidate nutritional modulator of muscle–adipose metabolic communication, causal mediation of the in vivo effects by SIRT1, FNDC5, or irisin requires further pathway-specific validation. In other words, the mouse study shows correlations—less weight gain, more irisin, more Ucp1—but does not yet prove, through knockout models or receptor blockade, that irisin is the indispensable messenger carrying the benefit from muscle to fat. Human trials, which would represent the ultimate test, remain on the horizon. Still, the convergence of in vitro pharmacology, live-animal outcomes, and a mechanistic framework anchored in one of the most extensively studied metabolic pathways gives the work unusual coherence.

For a field wrestling with rising obesity rates and the modest long-term success of lifestyle interventions alone, the appeal of a plant-derived molecule that amplifies an exercise-like hormonal signal is obvious. Syringaresinol is found in common plant foods, has a documented safety profile, and now demonstrates the ability to switch on the SIRT1–PGC-1α–FNDC5/irisin axis in both cells and living animals under obesogenic conditions. If future work confirms causality and translates to humans, the compound—or optimized derivatives of it—could become part of a nutritional strategy that works with the body’s own thermogenic machinery rather than against appetite. For now, the message is more measured but still compelling: a molecule hidden in plants may teach muscle to talk to fat in a language that favors staying lean.

Subject of Research: Activation of the skeletal muscle SIRT1–FNDC5/irisin axis by the plant lignan syringaresinol and its effects on diet-induced obesity

Article Title: Syringaresinol activates the skeletal muscle SIRT1–FNDC5/irisin axis to enhance weight management

Article References: Liu, S., Zhao, F., Azhati, S., Shan, W., Tao, B., Zhong, W., Wei, Y., Jiang, W., Zhao, K., & Liu, C. (2026). Syringaresinol activates the skeletal muscle SIRT1–FNDC5/irisin axis to enhance weight management. 3 Biotech, 16(10), Article 424. https://doi.org/10.1007/s13205-026-05027-z

Image Credits: AI Generated

DOI: 10.1007/s13205-026-05027-z

Keywords: syringaresinol, irisin, SIRT1, PGC-1α, FNDC5, skeletal muscle, adipose tissue browning, obesity, mitochondrial biogenesis, high-fat diet, lignan, weight management